文献速递眼底病与葡萄膜炎

3型新生血管(视网膜血管瘤样增生)抗VEGF治疗24个月真实世界结局

Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor: real-world outcomes at 24 months.
PubMed 文献 · Br J Ophthalmol · 2018-12-01

本研究基于真实世界登记数据,比较157眼视网膜血管瘤样增生(RAP)与469眼其他新生血管性年龄相关性黄斑变性(nAMD)亚型接受抗VEGF治疗的24个月结局。RAP组12个月和24个月视力均较基线显著提高,且12个月视力改善显著优于对照组,24个月时差异接近显著;RAP组灭活更早、活动性更低,两组注射次数中位数均为13次。

要点

  • RAP眼抗VEGF治疗后12个月和24个月视力均较基线显著提高。
  • RAP组12个月视力改善显著优于其他nAMD亚型,24个月时差异接近显著。
  • RAP组灭活更早且随访2年内活动性更低,两组注射次数中位数均为13次。

核心结论

  • RAP对anti-VEGF治疗反应良好,视力改善持续至24个月。
  • RAP在12个月和24个月视力结局优于其他nAMD亚型对照。
  • RAP倾向于更早灭活且2年随访期间活动性更低。

研究设计与样本

  • RAP组157眼,按基线视力、治疗起始年份、首次注射anti-VEGF药物和随访匹配选取非RAP nAMD对照469眼(每例3眼)。
  • 比较基线视力与12、24个月视力,以及视力变化、注射次数、活动性nAMD访视比例和首次灭活时间。

主要发现

  • RAP组基线视力(均值SD)61.4(15.5)字母,12个月升至68.7(14.7)字母(p<0.001),24个月为66.6(17.3)字母(p<0.001)。
  • RAP组12个月视力变化(均值95%CI)7.3(5.4至9.1)字母,对照组4.1(2.8至5.4)字母(p=0.01)。
  • RAP组24个月视力变化(均值95%CI)5.1(2.8至7.3)字母,对照组2.5(1至4)字母(p=0.056)。
  • 两组注射次数中位数均为13次;RAP组灭活更早且活动性更低(均p<0.001)。

临床怎么用

  • 真实世界中RAP接受anti-VEGF治疗可获得持续至24个月的视力改善。
  • RAP可能较其他nAMD亚型更早灭活、活动性更低,但仍需规范随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To compare 24 months outcomes of eyes with retinal angiomatous proliferations (RAPs) treated with antivascular endothelial growth factor (anti-VEGF) with a group of controls diagnosed with other neovascular age-related macular degeneration (nAMD) subtypes in a real-world setting. METHODS: Treatment-naïve nAMD eyes that commenced anti-VEGF between January 2006 and November 2015 were identified from a registry of nAMD treatment outcomes. Cases were defined as eyes diagnosed with RAP. Three controls per case were selected among nAMD eyes with non-RAP lesions and matched on baseline visual acuity (VA), year of treatment initiation, anti-VEGF agent first injected and follow-up. Baseline VA was compared with 12 and 24 months VA. Change in VA, number of injections received, proportion of visits with active nAMD and time to first inactivation were compared between RAPs and controls. RESULTS: 157 RAPs and 469 controls were included. Baseline VA (mean (SD)) increased at 12 months (61.4 (15.5) vs 68.7 (14.7) letters, p<0.001) and remained higher (66.6 (17.3) letters) at 24 months (p<0.001) in RAPs. The change from baseline VA (mean(95% CI)) was significantly higher in RAPs than in controls at 12 months (7.3 (5.4 to 9.1) vs 4.1 (2.8 to 5.4) letters, p=0.01) and at 24 months (5.1 (2.8 to 7.3) vs 2.5 (1 to 4) letters, p=0.056). Both groups received a median of 13 injections. RAPs inactivated earlier and were less active than controls (both p<0.001). CONCLUSIONS: RAPs responded well to anti-VEGF, with a significant improvement in VA persisting at 24 months. RAPs had better visual outcomes than controls at 12 and 24 months, tended to inactivate earlier and were less active throughout 2 years follow-up.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Invernizzi A, Teo K, Nguyen V, et al. Type 3 neovascularisation (retinal angiomatous proliferation) treated with antivascular endothelial growth factor: real-world outcomes at 24 months. Br J Ophthalmol. 2018. PMID: 30504490. doi:10.1136/bjophthalmol-2018-312944

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。